spartalizumab (PDR001) / Novartis  >>  Phase 2
Welcome,         Profile    Billing    Logout  

14 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
spartalizumab (PDR001) / Novartis
2020-003022-22: SOLTI-1904: EfficACy of Spartalizumab acROss multiPle cancer-types in patients with PD1-high mRNA expressing tumOrs defined by a singLe and pre-specIfied cutoff (ACROPOLI trial) SOLTI-1904: Eficacia de spartalizumab en múltiples tipos de cáncer en pacientes con tumores con expresión elevada de ARNm de PD1, definida según un punto de corte preespecificado (ensayo ACROPOLI)

Not yet recruiting
2
141
Europe
Spartalizumab, PDR001, Concentrate for solution for infusion
SOLTI, Novartis Pharma AG
Metastatic disease Enfermedad metastásica, Metastatic disease Enfermedad metastásica, Diseases [C] - Cancer [C04]
 
 
NCT03785496: Study to Evaluate Efficacy of PDR001 in Patients With Squamous Cell Carcinoma of the Esophagus

Active, not recruiting
2
44
RoW
PDR001
Yonsei University
Histologically Confirmed Unresectable or Metastatic Squamous Cell Carcinoma of the Esophagus Who Failed on Standard Treatment
01/22
01/24
NCT03668431: Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

Recruiting
2
25
US
Dabrafenib, Tafinlar®, Trametinib, Mekinist®, PDR001
Massachusetts General Hospital, Novartis, Stand Up To Cancer
Metastatic Colorectal Cancer
09/22
12/22
NCT04323436 / 2019-003097-11: Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Terminated
2
31
Europe, Canada, Japan, US, RoW
Spartalizumab, PDR001, Capmatinib, INC280, spartalizumab placebo, PDR001 placebo
Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
12/22
01/23
CNIR178X2201, NCT03207867 / 2017-000241-49: A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Terminated
2
315
Europe, Japan, US, RoW
NIR178, taminadenant, PDR001, spartalizumab
Novartis Pharmaceuticals
NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer, Urothelial Cancer, Head and Neck Cancer, DLBCL, Diffused Large B Cell Lymphoma, MSS, Microsatellite Stable Colon Cancer, TNBC, Triple Negative Breast Cancer, Melanoma, mCRPC, Metastatic Castration Resistant Prostate Cancer
02/23
02/23
ALTER-PATH NeoDT, NCT04310397: Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Completed
2
4
US
Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Spartalizumab, PDR-001, PDR001, Therapeutic Conventional Surgery, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
M.D. Anderson Cancer Center
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
10/23
10/23
SPARTANA, NCT04894370: Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma

Recruiting
2
34
Europe
Sample collection
Centre Hospitalier Universitaire de Besancon, National Cancer Institute, France, Novartis
Squamous Cell Anal Carcinoma, Metastatic Squamous Cell Carcinoma
06/25
11/26
GASPAR, NCT04736485 / 2020-004497-21: Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)

Active, not recruiting
2
67
Europe
perioperative treatment
Centre Francois Baclesse, National Cancer Institute, France
Gastric Cancer by AJCC V8 Stage, Resectable Carcinoma
03/24
03/27
daNIS-1, NCT04390763 / 2020-000349-14: Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Terminated
2
164
Europe, US, RoW
NIS793, Spartalizumab, PDR001, gemcitabine, nab-paclitaxel, abraxane
Novartis Pharmaceuticals
Metastatic Pancreatic Ductal Adenocarcinoma
04/24
05/24
NCT04544111: PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Active, not recruiting
2
19
US
Trametinib, Dabrafenib, PDR001
Memorial Sloan Kettering Cancer Center
Thyroid Cancer, Thyroid Cancer, Follicular, Papillary Thyroid Cancer, Follicular Thyroid Cancer, Hurthle Cell Tumor, Poorly Differentiated Thyroid Gland Carcinoma, Hurthle Cell Thyroid Neoplasia
09/25
09/25
ACROPOLI, NCT04802876: Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors

Recruiting
2
184
Europe
Spartalizumab, PDR001, Tislelizumab
SOLTI Breast Cancer Research Group, Novartis
MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma, Mesothelioma, Triple Negative Breast Cancer, Lung Adenocarcinoma, Cholangiocarcinoma, Cervical Carcinoma, Kidney Clear Cell Carcinoma, Stomach Adenocarcinoma, Esophageal Adenocarcinoma, Uterine Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Sarcoma, Lung Squamous Cell Carcinoma, Urothelial Carcinoma, Thyroid Carcinoma, Hepatocellular Carcinoma, Uveal Melanoma, HER2-positive Breast Cancer, Pancreatic Adenocarcinoma, Squamous Esophageal Carcinoma, Epithelial Ovarian Cancer, Uterine Carcinosarcoma, Small Cell Lung Cancer, Hormone Receptor Positive / HER2-negative Breast Cancer, Lung Adenocarcinoma EGFR-mutated/ ALK Traslocation, Colorectal Adenocarcinoma, Prostate Adenocarcinoma, Carcinoma of Unknown Primary, Other Histology
09/25
03/27
NCT05201066: Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Recruiting
2
70
Europe, US, RoW
decitabine, spartalizumab, PDR001, sabatolimab, MBG453, azacitidine, venetoclax, INQOVI (oral decitabine)
Novartis Pharmaceuticals
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
09/27
02/28
NCT04191421: Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

Completed
1/2
42
US
Siltuximab, Anti-IL-6 Chimeric Monoclonal Antibody, cCLB8, CNTO 328, Sylvant, Spartalizumab, PDR001
Emory University, Novartis, EUSA Pharma, Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
04/23
04/23
SPARTO, NCT05210413: Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults

Recruiting
1/2
59
Europe
Spartalizumab in Pediatric cohort, Low-dose Pazopanib in Pediatric Cohort, Spartalizumab in Adult cohort, Low-dose Pazopanib in Adult Cohort
University Hospital, Bordeaux, National Cancer Institute, France, Fondation ARC, Novartis
Refractory or Recurrent Solid Tumor
11/26
11/27

Download Options